![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 10, 2022 12:46:03 PM
The active group is a lot harder to treat as evidenced by the PI data. In 8 patients (technically 6 but 2 were dosed twice) there was only 1 complete response and 1 partial response. All of these patients failed multiple lines of therapy. I believe the lowest number of prior therapies failed was 4. These particular patients are clearly running out of options. The CR is obviously positive but this is such a small data set that it is hard to use it as an effective measure of how the PII is going to go. That being said I personally believe that if the PII results can match the PI results we should be ok.
I've touched on this in the past but will just recap a little since the data readout is closer now. This therapy needs to be compared to Donor Lymphocyte Infusions (DLIs). DLIs are given after relapse post stem cell transplant. So the same space Marker is running this PII trial in. They are typically only used for patients who are in very good shape, all else considered, but are very toxic and very expensive. The ORR for DLIs is anywhere between 5%-10%. The main issue with a DLI is Graft vs Host Disease (GvHD) where the donor cells attack the recipient’s healthy cells. The incidence of GvHD in these patients ranges from 40%-60% with 20%-35% being grade 3 or 4.
Even if MultiTAA can just match the response rates of DLIs, ~10% on the high end, it should be approvable based on the extremely favorable safety profile. Not only would it then be a better option for those that would be eligible for a DLI it should also be an option for those that would not have been eligible for a DLI.
The PI CR rate was ~12%. Again, this was based of of 8 patients so we can't really assume those results will carry forward into the PII. However, if they do we would expect to see at least 5 CRs out of the total 40 patients. The upcoming readout will be on 20 patients so it would be nice to see 2 or 3 CRs but I will hold judgement for the full data readout which could come in the middle of the year. I would guess beginning of Q3.
One last note. They are continuing to make manufacturing improvements. They cut the manufacturing time down 50% over the original BCM process and are working towards reducing it another 50% for a total of 75% reduction in manufacturing time. Along with the other improvements they made we should hopefully see improved results in the PII. They are also looking into developing an off the shelf therapy which could be a big step forward if they can manage it. I don't expect it to come soon but it's something to keep an eye out for.
Friends don't let friends place market orders
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM